Sequoia Pharmaceuticals Announces Appointment of Steven D. Skolsky as Chief Executive Officer

    GAITHERSBURG, Md., Oct. 29 /PRNewswire/ -- Sequoia Pharmaceuticals,
 Inc., which discovers and develops novel antiviral therapeutics as well as
 pharmacokinetic enhancers, announced today the appointment of Steven D.
 Skolsky as its President and Chief Executive Officer. He will also serve as
 a member of the Board of Directors.
     "Sequoia is pleased to have recruited such an outstanding, talented
 leader as Steven Skolsky," said Chris Mirabelli, Chairman of the Board of
 Sequoia Pharmaceuticals. "Steve has an impressive record of success within
 the pharmaceutical industry. The combination of his leadership and
 management experience, as well as his business acumen, makes Steve uniquely
 qualified to lead us through the exciting times ahead."
     "Sequoia possesses an extraordinary scientific pedigree, and a very
 attractive research portfolio. I am honored to have the opportunity to lead
 Sequoia, and to build on its outstanding technological progress as we move
 towards commercialization", said Mr. Skolsky.
     Mr. Skolsky brings over twenty-five years of U.S. and international
 experience in the pharmaceutical and biotechnology arena. He most recently
 served as chief executive officer of Trimeris, a biotechnology company
 specializing in HIV therapeutics. Previously Mr. Skolsky had a
 distinguished career at GlaxoSmithKline where he served as GSK's Senior
 Vice President of Global Commercial Strategy responsible for world-wide
 clinical development and product strategy. He also served as managing
 director of GSK's operations in Australia and New Zealand and previously
 was Vice President of Sales and Marketing of the HIV/Oncology Division at
 Glaxo Wellcome. He is a graduate of the University of North Carolina at
 Chapel Hill.
     About Sequoia Pharmaceuticals, Inc.
     Sequoia Pharmaceuticals discovers and develops revolutionary new
 treatments, primarily for viral diseases including HIV/AIDS and HCV-induced
 hepatitis. In addition, Sequoia has an active R&D program in
 pharmacokinetic enhancers.
 
 

SOURCE Sequoia Pharmaceuticals, Inc.